Pharmaceutical giant Eli Lilly has partnered with AbCellera Biologics, a biotechnology company based in Canada, to address the new coronavirus crisis by developing antibody products to treat and prevent the virus, The Wall Street Journal reported.
AbCellera uses machine learning to find antibody therapies and received a blood sample in February from a patient diagnosed with COVID-19. By screening more than 5 million immune cells and using machine learning to identify which can produce antibodies to neutralize COVID-19, AbCellera identified more than 500 promising antibodies in less than one week.
AbCellera is just one of many companies in the space leveraging AI and machine learning to deal with the pandemic and find desperately-needed solutions.
See the full story below:
Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."